Pfizer Inc. (PFE)
This Beaten-Down Stock Just Gave Investors More Good News: Is it a Buy?
Slowly but surely, the company's prospects are looking more attractive.
3 Potential Catalysts That Could Lift Pfizer Stock Before 2025
The pipeline could yield a winner, but so could a few organizational changes.
Pfizer Is A Good Stock To Buy After The Earnings
PFE has beaten analyst estimate both top- and bottom line. The firm has also raised its full-year guidance. Investors have not taken the earnings news too positively, however, because significant portion of the growth has been driven by Covid-19 related products or non-recurring items. Based on a single stage dividend discount model and a set of traditional price multiples, PFE appears to be undervalued.
Baby Boomers: 2 Super-High-Yield Stocks to Watch in November
Baby Boomer investors who aren't happy with the falling rates on their savings and CDs may be enticed by the dividend stocks right about now.
Pfizer: Overstated Pessimism Makes Little Sense
Pfizer scored a double beat on revenue and adjusted EPS, bolstered by the surprising performance of its COVID franchise. Despite that, the lukewarm post-earnings response suggests Pfizer needs to flex its muscles on its ex-COVID growth optionalities. PFE has likely moved past its long-term lows in early 2024, underscoring the market's conviction that the worst is over.
Pfizer CEO on Q3 earnings, exceptional with phenomenal growth
After Pfizer (PFE) posted a third quarter earnings beat and raised its full-year guidance, CEO Albert Bourla joins Market Domination to discuss the "exceptional quarter." Bourla notes that Pfizer in addition to earnings and revenue, the company's COVID and non-COVID businesses also topped expectations.
3 Factors That Make Pfizer's Ultra-High-Yield Dividend Safer Than You Might Think
Pfizer's dividends should keep flowing and growing.
Pfizer Covid sales boost prompts durability concerns - Bank of America
Pfizer Inc (NYSE:PFE, ETR:PFE)'s reliance on a rebound in demand for Covid-19 products in expectation-beating third-quarter results likely hit sentiment, according to Bank of America analysts. Though the drug maker hiked guidance on better-than-estimated revenue on Tuesday, shares fell by 1.8% following the results.
3 Stocks to Buy Following Robust Quarterly Results
Throughout the Q3 reporting cycle, several companies, including Pfizer, Philip Morris, and Tenet Healthcare, have stolen the spotlight, with each raising guidance.
Here's Why Pfizer (PFE) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Pfizer Stock Tumbled on Tuesday
The specter of an activist investor looms over the company.
Pfizer CEO says he welcomes good ideas as Starboard ups pressure on company
In a Tuesday interview with CNBC's Jim Cramer, Pfizer CEO Albert Bourla struck a positive tone about activist investor Starboard Value, saying he agreed with some of its criticisms, but maintained that the company is headed in a good direction. "I think we are doing a lot of changes.
